Published in Br J Haematol on December 01, 2002
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood (2007) 1.27
Pharmacotherapy in sickle cell disease--state of the art and future prospects. Br J Haematol (2009) 0.92
Hydroxyurea therapy mobilises arachidonic Acid from inner cell membrane aminophospholipids in patients with homozygous sickle cell disease. J Lipids (2011) 0.77
Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros. Rev Bras Hematol Hemoter (2011) 0.75
Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med (2004) 10.51
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol (2007) 2.76
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
Circumstances of death in adult sickle cell disease patients. Am J Hematol (2006) 1.74
Hepatitis C virus in sickle cell disease. J Natl Med Assoc (2003) 1.68
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood (2008) 1.61
Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc (2008) 1.51
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
HCV in sickle cell disease. J Natl Med Assoc (2003) 1.39
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA (2011) 1.38
Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis (2003) 1.29
Genetic screening for iron overload: No evidence of discrimination at 1 year. J Fam Pract (2007) 1.27
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol (2010) 1.25
Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. Am J Cardiol (2009) 1.22
Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care (2006) 1.20
Depression in sickle cell disease. J Natl Med Assoc (2003) 1.18
Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol (2008) 1.15
Pulmonary hypertension of sickle cell disease beyond classification constraints. J Am Coll Cardiol (2014) 1.09
Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr (2011) 1.05
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol (2008) 1.04
Frequent and prolonged hospitalizations: a risk factor for early mortality in sickle cell disease patients. Am J Hematol (2003) 1.01
Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises. Am J Med Sci (2003) 0.99
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica (2006) 0.99
Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study. Am J Hematol (2007) 0.94
Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol (2003) 0.94
Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea; Hemoglobinopathy. Hematology (2000) 0.90
Genetic determinants of haemolysis in sickle cell anaemia. Br J Haematol (2013) 0.89
Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study. Clin Ther (2005) 0.89
Laboratory and echocardiography markers in sickle cell patients with leg ulcers. Am J Hematol (2011) 0.89
Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea. Hematology (2004) 0.88
Hydroxyurea treatment of sickle cell anemia in hospital-based practices. Am J Hematol (2002) 0.87
Bacillus anthracis endospores regulate ornithine decarboxylase and inducible nitric oxide synthase through ERK1/2 and p38 mitogen-activated protein kinases. Curr Microbiol (2010) 0.85
Fluorescence measurements of the labile iron pool of sickle erythrocytes. Blood (2003) 0.84
Effects of hydroxyurea and L-arginine on the production of nitric oxide metabolites in cultures of normal and sickle erythrocytes. Hematology (2006) 0.82
Accuracy of family history of hemochromatosis or iron overload: the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol (2008) 0.82
Arterialization of peripheral venous blood in sickle cell disease. J Natl Med Assoc (2002) 0.79
Low cobalamin levels in African Americans with and without sickle cell disease. J Natl Med Assoc (2006) 0.79
Case 17-2005: acute chest syndrome and ARDS. N Engl J Med (2005) 0.78
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.77
Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Transl Res (2007) 0.76
Effects of External and Internal Hyperthermia on LDL Transport and Accumulation Within an Arterial Wall in the Presence of a Stenosis. Ann Biomed Eng (2014) 0.76
Physician-assisted suicide. Crit Care Med (2009) 0.75
Reply: Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption. Am J Respir Crit Care Med (2014) 0.75
The celestial fire of conscience. N Engl J Med (2005) 0.75
Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia. Eur J Haematol (2014) 0.75
Pulmonary hypertension in sickle cell disease. N Engl J Med (2011) 0.75
Hematuria in sickle cell trait: the importance of ruling out occult cancer. Ann Hematol (2011) 0.75
Use of a prenatal risk screen to predict maternal traumatic pregnancy-associated death: program and policy implications. Womens Health Issues (2013) 0.75
Jewish medical ethics in the care of the cancer patient. J Relig Health (1988) 0.75
Perceptions of communication in the operating room: a pilot survey study. J Med Pract Manage (2015) 0.75
Quantitative analysis of trimethylsilyl derivative of hydroxyurea in plasma by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.75
Central retinal vein occlusion in sickle cell disease. South Med J (2004) 0.75
Novel improvements in perioperative sterility. J Med Pract Manage (2015) 0.75
The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. 1976. J Urol (2002) 0.75
Jewish bioethics and medical genetics. J Relig Health (1994) 0.75
Arterialization of venous blood for differentiation of sickle cell subjects in vaso-occlusive crisis. Hematology (2003) 0.75
Jewish biomedical ethics and care of the AIDS patient. J Relig Health (1993) 0.75